Cyclacel Pharmaceuticals

View the org chart displaying its 8 main executives

Most searched biographies at Cyclacel Pharmaceuticals

• Spiro Rombotis, President, Chief Executive Officer, Director
• Samuel Barker, Director
• Christopher Henney, Chairman of the Board

Popular executive movements at Cyclacel Pharmaceuticals

• Brian Schwartz, who was Director, is promoted to Chief Medical Officer and Director  (posted on January 30 2024).
• Mark Kirschbaum, Senior Vice President and Chief Medical Officer, has left the company  (posted on January 30 2024).

Create your alert
to follow the executive moves at Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals has 1,869 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Cyclacel Pharmaceuticals

• Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results | Cyclacel Pharmaceuticals, Inc.
• RSS News Feeds | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020 | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
• CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING | Cyclacel Pharmaceuticals, Inc.
• View more press releases Close

Social media about Cyclacel Pharmaceuticals

• Cyclacel Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Cyclacel Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Spiro Rombotis

Call Cyclacel Pharmaceuticals at +1 908...

View the org chart

Register to receive your alert

Report an error